De-escalation strategy with half-dose prasugrel or ticagrelor on pharmacodynamics and outcome in East Asians patients with acute coronary syndrome
Sign Up to like & getrecommendations! Published in 2020 at "European Heart Journal"
DOI: 10.1093/ehjci/ehaa946.1729
Abstract: East Asians treated with potent P2Y12 inhibitors (prasugrel or ticagrelor) are exposed to more potent platelet inhibitory response. Whether half-dose de-escalation strategy would be benefit for chronic antiplatelet strategy in East Asian patients with acute… read more here.
Keywords: half dose; prasugrel; ticagrelor; half ... See more keywords
Unguided De-Escalation Strategy From Potent P2Y12 Inhibitors in Patients Presented With ACS: When, Whom and How?
Sign Up to like & getrecommendations! Published in 2022 at "Korean Circulation Journal"
DOI: 10.4070/kcj.2022.0022
Abstract: https://e-kcj.org In patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI), dual antiplatelet therapy (DAPT) is an essential strategy of their management. According to the current guidelines, it is generally recommended to… read more here.
Keywords: unguided escalation; strategy; escalation strategy; potent p2y12 ... See more keywords